One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.

Date publication

février 2016

Journal

Transplantation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUCLOUX Didier

Tous les auteurs :
Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26555944

Résumé

Treatment of acute antibody-mediated rejection (AMR) is based on a combination of plasma exchange (PE), IVIg, corticosteroids (CS), and rituximab, but the place of rituximab is not clearly specified in the absence of randomized trials.

Mots clés

Acute Disease, Adult, Biomarkers, blood, Biopsy, Creatinine, blood, Double-Blind Method, Female, France, Glomerular Filtration Rate, drug effects, Graft Rejection, diagnosis, Graft Survival, drug effects, Humans, Immunosuppressive Agents, adverse effects, Kidney, drug effects, Kidney Transplantation, adverse effects, Male, Middle Aged, Prospective Studies, Recovery of Function, Rituximab, adverse effects, Time Factors, Treatment Outcome

Référence

Transplantation. 2016 Feb;100(2):391-9